Compare And Contrast Three Drug Diabetes

Corporations and business organizations have to face lawsuits due to breach of different laws i.e., consumers laws, copyright laws, compensation laws, security laws, antitrust, employment or environmental laws. For violating any of these laws companies have to pay fines and even go bankrupt. Current paper is a report on one such lawsuit that caused GlaxoSmithKline loss of billions of dollars. The author selected "Avandia Lawsuit" to focus in this report. Avandia is a drug used to treat type 2 diabetes and was prepared by GlaxoSmithKline which was approved by U.S Government in 1998 and became best selling drug. Company generated profit through its sale but soon complains arose due to increasing incidences of heart disease and stroke as side effect of the drug.

Podcast “Race and Medline” talks about how some researchers started to test a drug to see if it can help with heart failure. After they asked the FDA to make this drug into a pill they said no because the research trial was too small. Then they started to think about

Diabetes Mellitus (DM) or Type 2 Diabetes is seen as a metabolic disease that is categorized by abnormally high blood glucose or hyperglycemia. Diabetes Mellitus is also formerly known as noninsulin-dependent diabetes mellitus and is the most common form of diabetes that is seen. Insulin is a hormone that is supplied to the body that allows us to efficiently use glucose as fuel. When carbohydrates are broken down into sugars in the stomach glucose enters the blood circulation simulating the pancreas to release insulin in an appropriate amount to become used for energy. With diabetes mellitus the body does not properly make use of the insulin supplied for the body. This causes the pancreas to produced an extra amount if insulin which the body cannot keep up with, causing an imbalance to the blood glucose levels (American Diabetes Association, 2015). In the united states diabetes affects almost 29.1 million people, while the another 86 million people have pre-diabetes but do not know. It is also known as the 7th leading cause of death in the country in the recent years (MedicineNet.com, 2016). For a patient suffering from a chronic form of diabetes mellitus understanding how these mechanisms lead to the condition can be used as preventative measures. Potential consequences as well as the causes and clinical manifestations will ensure a better knowledge on the issue to monitor the condition.

29 million people in the United States (9.3 percent) have diabetes, and of those 29 million approximately 7.25 million are unaware that they are diabetic (www.cdc.gov). Diabetes describes a group of metabolic diseases in which the person has high blood glucose because insulin production is inadequate, or because the body 's cells do not respond properly to insulin, or both. Diabetes can be divided into two groups: Type 1 diabetes and Type 2 diabetes. Type 1 diabetes is also referred to as juvenile diabetes and is usually found in children and young adults. Only 5% of people with diabetes have this form of the disease. Type 1 diabetes restricts the body from producing insulin, a hormone that is needed to convert sugar, starches and other food into energy needed for daily life. Type 1 diabetes can be managed by using insulin therapy and other treatments to help those infected maintain insulin to convert sugars, starches and foods into energy(www.diabetes.org). Type 2 diabetes is the most common, people with Type 2 diabetes have insulin resistance meaning the body does not use insulin properly. At first, the pancreas makes a surplus insulin to compensate for the lack on insulin in your body. However, over time your pancreas is not able to keep up and can not make enough insulin to keep your blood glucose at normal levels(www.diabetes.org). Complications of diabetes in the long term include potential heart disease, stroke, and kidney damage.

The drug corporation place profit above human life while the drug cause complexion of issues relates clinical data on Avandia with a bias report that the medication was safe. Consequently, the Avandia drug many adverse side effects that were generating heart trouble and death to the many of the diabetic patients taking the drug. Therefore, we will learn how the first step in research is essential that there is no bias and that the formulation of the investigation will determine failure or success, the drug companies imply that the study is valid as true, without proof that leads to bias in the pharmaceutical companies that are manufacturing medicinal drugs. The Know bias that I, as a customer how the drug industry money influences over research.

The growth of type one diabetes has been increasing over the past decades. The rise of this disease could be contributed to many factors such as, environmental factors, hereditary, lifestyle choices, and etc. The United States and Finland are rated among some of the highest counties experiencing high growth of type one diabetes. Children of the age range anywhere from ages one to sixteen have been contributing to the increase of type one diabetes within the United States and Finland.

We aim to improve the process by which diabetic medication is administered in the medical surgical unit. The process begins with nurses reviewing medication orders and ends when patient receives medication. By working on the process we expect better patient outcomes as evidence by better controlled serum glucose levels and fewer instances of patient hyper/hypoglycemic episodes. It is important to work on this now because uncontrolled blood glucose levels can cause longer hospital stays, increased risk of infection, and initiation of new, additional comorbidities.

Organization alarmed the GlaxoSmithKline regarding the effects of Avandia. Later on, GSK carried meta-analysis. In 2008, it was essayed that the drug

Considerable advances in the past treatment of type II diabetes include the application of lifestyle intervention and prevention efforts aimed at delaying development of glucose intolerance in order to evade diabetes and the progression of new curricula of glucose in the blood-lowering prescriptions to appendage current treatments (DeFronzo, 2010) (Mazzola, 2012). Presently, the control and maintenance of type II diabetes centres on control of glucose by the decrease of haemoglobin and glucose in the blood (DeFronzo, 2010). Current treatment strategies focus on the progression of therapeutic factors that affect the defects contributing to type II diabetes and thus, provide sustainable glucose control through a delaying of disease development

Diabetes is a serious medical condition that can also be a risk factor for the development of many different diseases and conditions including dementia, heart disease, and CVA. Thus, effective management of diabetes is very important. Patient compliance can be difficult to achieve if the person affected with diabetes is not educated about the illness or treatment, has not fully accepted the diagnosis or its severity, will not change habits or believes that the prescribed treatment regime is too difficult or ineffective, has cultural beliefs conflicting with the treatment regime, experiences stressful events, lacks social support, or suffers from psychiatric issues unrelated to diabetes (Gerard, Griffin, & Fitzpatrick, 2010). As one may expect, adequate education programs are essential tools when dealing with diabetics. Solid education will provide the patient with information as well as teaching the necessary skills to manage the disorder. The primary focus of any diabetes education program must be to empower patients as a part of the multidisciplinary team. This team should be focused at integrating diabetes into the lives of the patients and this focus should be based on the decisions made by the patient, otherwise the treatment plan can be looked on as forced (Gerald et al., 2010). Every patient stricken with diabetes has the right to benefit from an education program of this type. First, basic education and facts should be administered directly following the diagnosis of

Pt able to verbalize proper medication and diabetes management techniques without assistance at the end of the first treatment session so that they are able to properly manage their medications and diabetes to assist with wound healing and preventing future wounds.

Diabetes mellitus is due to a lack of insulin production from beta cells in the pancreas resulting in an insufficient amount of insulin to be able to regulate the bodies blood sugar levels. This causes insulin resistance which is the inability of cells to respond properly to insulin in the fat tissues, muscles and liver. What normally happens in the liver is insulin suppresses glucose synthesis if the levels in the blood are to high and causes the cells especially in the liver to take in glucose and store it as glycogen. However during insulin resistance the liver continuously breaks down glycogen in glycogenolysis to release glucose into the blood. Once liver is saturated with

Overall, nearly 60% of our corresponding authors were academic researchers and 37.5% clinical investigators. Surprisingly, only 3.1% of the corresponding authors reported to be a pharmaceutical employee despite 38% of the selected clinical trial articles were pharmaceutical funded.

Lo C, Toyama T, Hirakawa Y, Jun M, Cass A, Hawley C, Pilemore H, Badev SV, Percovic V, Zoungas S. Insuline & Glucose lowering agents for treating people with diabetics and chronic Kidney disease. Cochrane Database of systematic reviews 2015, Issue 8. Art. No. CD011798. DOI:10.1002/14651858.CD011798.

Glitazones are the new class of anti-diabetic drugs that are the first to be able to manage glycaemia goals. Troglitazone was first approved for the market in 1997, but it was withdrawn from the market by 2000. After the withdrawal of troglitazone, rosiglitazone and pioglitazone were introduced in 1999 as potentially safer alternatives. However, currently rosiglitazone is under black box warning for increased risk of cardiovascular disease and pioglitazone is in a nutshell as the drug required more investigation. In this review, the potential ability to predict the adverse drug reactions (ADRs) are examined. If it is possible to predict ADRs, should it be done in the future.